Search details
1.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-38437622
2.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood
; 139(7): 1026-1038, 2022 02 17.
Article
in English
| MEDLINE | ID: mdl-34496014
3.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32688395
4.
CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
Br J Haematol
; 193(3): 449-465, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33222167
5.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med
; 377(26): 2545-2554, 2017 12 28.
Article
in English
| MEDLINE | ID: mdl-29226764
6.
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Biol Blood Marrow Transplant
; 25(12): 2305-2321, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31446199
7.
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
N Engl J Med
; 384(7): 673-674, 2021 02 18.
Article
in English
| MEDLINE | ID: mdl-33596362
8.
No CNS sanctuary for lymphoma from CAR T.
Blood
; 139(15): 2261-2263, 2022 04 14.
Article
in English
| MEDLINE | ID: mdl-35420689
9.
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Blood
; 134(21): 1873-1875, 2019 11 21.
Article
in English
| MEDLINE | ID: mdl-31554634
10.
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
Br J Haematol
; 170(4): 504-14, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25907897
11.
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Cancer
; 120(2): 222-8, 2014 Jan 15.
Article
in English
| MEDLINE | ID: mdl-24122387
12.
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Blood
; 129(8): 1039-1041, 2017 02 23.
Article
in English
| MEDLINE | ID: mdl-28031179
13.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Transplant Cell Ther
; 2024 Mar 16.
Article
in English
| MEDLINE | ID: mdl-38494076
14.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
J Hematol Oncol
; 17(1): 19, 2024 Apr 22.
Article
in English
| MEDLINE | ID: mdl-38644469
15.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
NEJM Evid
; 3(4): EVIDoa2300213, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38776868
16.
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nat Med
; 30(4): 984-989, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38266761
17.
The CNS Relapse in T-Cell Lymphoma Index Predicts CNS Relapse in Patients with T- and NK-Cell Lymphomas.
Blood Adv
; 2024 May 13.
Article
in English
| MEDLINE | ID: mdl-38739715
18.
TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.
Blood Adv
; 7(23): 7243-7253, 2023 12 12.
Article
in English
| MEDLINE | ID: mdl-37851898
19.
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
Clin Transl Radiat Oncol
; 39: 100587, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36718252
20.
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
Transplant Cell Ther
; 29(8): 495-503, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37211154